RecruitingPhase IIEN original
Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
NCT05536128Original on ClinicalTrials.gov ↗
⚠️
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Protocol Title: A Phase II open label, umbrella study evaluating the efficacy and safety of Fulvestrant plus DNA damage repair inhibitors in hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zdolność do podpisania świadomej zgody na uczestnictwo w badaniu
- •Wiek co najmniej 19 lat
- •Rak piersi przerzutowy lub nieoperacyjny typu HR+/HER2-
- •Progresja choroby po leczeniu hormonalnym i inhibitorem CDK4/6
- •Prawidłowa funkcja organów i szpiku kostnego: hemoglobina ≥10,0 g/dL, neutrocyty ≥1,5 x 10⁹/L, płytki ≥100 x 10⁹/L
- •Prawidłowe parametry wątroby: bilirubina całkowita ≤1,5 x górna granica normy, transaminazy ≤2,5 x górna granica normy
- •Klirens kreatyniny ≥51 mL/min
- •Stan ogólny ECOG 0-1 i oczekiwana przeżywalność ≥16 tygodni, co najmniej jedna zmiana guza widoczna w badaniach obrazowych
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- April 17, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Seoul National University Hospital
Seoul, South Korea
Trial contact
Seock-Ah Im
Kyung-Hun Lee, MD
SUB_INVESTIGATOR
Dae-Won Lee, MD
SUB_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.